In this guide
What is red clover?
Red clover is Trifolium pratense, a legume whose aerial parts contain isoflavones including biochanin A, formononetin, genistein and daidzein. Standardized extracts are promoted mainly for menopause-related hot flashes. They are not the same exposure as tea, whole herb or food legumes. [1], [5]
The current evidence is mixed. A meta-analysis reports a modest average reduction, while two informative placebo-controlled trials did not show a clinically important benefit. Baseline symptom burden, product composition and placebo response affect the conclusion. [1]–[3]
Typical Red Clover Protocols
| Source and context | Material | Amount | Frequency | Duration | Observed outcome |
|---|---|---|---|---|---|
| Tice 2003 ICE trial · 252 women with at least 35 hot flashes/week | Promensil or Rimostil standardized isoflavone extracts | 82 mg/day total isoflavones or 57 mg/day total isoflavones | Daily; within-day timing not reported in the abstract | 12 weeks after a 2-week placebo run-in | Final reductions 5.1, 5.4 and 5.0 hot flashes/day for Promensil, Rimostil and placebo Promensil acted faster, but neither product produced a clinically important final benefit. |
| Geller 2009 · 89 women in four arms | Standardized ethanolic aerial-parts extract | 398 mg extract/day supplying 120 mg isoflavones/day | Daily; within-day timing not reported | 12 months | 57% vasomotor reduction versus 63% with placebo No significant benefit over placebo; extract and isoflavone milligrams are not interchangeable. |
| van de Weijer 2002 · 30 women with more than 5 hot flashes/day | Promensil | 80 mg/day isoflavones | Daily; within-day timing not reported | 12 weeks after a 4-week placebo run-in | 44% further reduction during active phase versus no further placebo reduction Very small named-product trial; placebo run-in and selected population limit generalization. |
| Kanadys 2021 review · eight trials, ten comparisons | Standardized red-clover isoflavone extracts | Varied; subgroup signal at 80 mg/day or more | Schedules varied by trial | Commonly 12 weeks | Pooled difference −1.73 hot flashes/day Subgroup patterns are exploratory and do not define a universal regimen. |
There is no RDA, AI or established UL for red clover or its isoflavones. Total extract mass cannot be converted to isoflavone content unless the label supplies both.
- Titration
- No validated general self-titration is established. Increasing extract mass does not predict a proportional isoflavone or symptom effect.
- Timing
- The highlighted sources report daily totals; they do not establish a universal time of day or split schedule.
- Duration
- Highlighted trials lasted 12 weeks to 12 months. They do not establish indefinite use.
- Stopping
- No standard taper is established. Stop and seek review for unusual bleeding, allergic symptoms or a pregnancy.
Three outcomes, separate conclusions
Keep isoflavone amount, placebo response and outcome visible.
Pooled estimate: 1.73 fewer per day.
ICE and Geller trials did not show clinical benefit.
Lipids, bone and safety remain inconclusive.
What is red clover commonly used for?
Red clover is promoted for hot flashes, night sweats, cholesterol, bone health and other menopause concerns. Hot flashes have the largest clinical literature, yet the results remain inconsistent. Cholesterol studies conflict and bone-density studies are few and inconsistent. [1], [5]
Which form and label details matter?
- Species and part: Trifolium pratense, often aerial parts.
- Extract versus isoflavones: record both total extract and total isoflavones per day.
- Isoflavone profile: biochanin A, formononetin, genistein and daidzein proportions vary.
- Named product: Promensil, Rimostil and other extracts should not inherit one another's results.
- Combination ingredients: probiotics or other botanicals prevent attribution to red clover alone.
- Reproductive and medicine context: pregnancy, breastfeeding, hormone-sensitive disease and medicines affecting clotting require review.
What does the human evidence show?
Hot flashes and menopause symptoms
Kanadys and colleagues pooled eight randomized trials with ten comparisons. Red clover was associated with 1.73 fewer hot flashes per day than placebo (95% CI −3.28 to −0.18). Subgroup patterns were stronger in studies lasting 12 weeks, using at least 80 mg/day isoflavones, enrolling women with at least five hot flashes per day and using more biochanin A. Those post hoc patterns cannot establish a best dose or product. [1]
The ICE trial enrolled 252 women after a two-week placebo run-in. At 12 weeks, daily hot-flash reductions were 5.1 with Promensil 82 mg/day total isoflavones, 5.4 with Rimostil 57 mg/day and 5.0 with placebo. Promensil reduced symptoms faster, but final hot-flash and quality-of-life differences were not clinically important. [2]
Geller and colleagues followed 89 women for 12 months. Vasomotor symptoms fell 57% with a 398 mg/day extract supplying 120 mg/day isoflavones and 63% with placebo. Neither red clover nor black cohosh significantly beat placebo. [3]
A smaller 30-person trial reported a 44% further decrease after 80 mg/day Promensil during the double-blind phase. Its size, placebo run-in and named product make it supportive but not decisive. [4]
Lipids, bone and hormone-sensitive outcomes
NCCIH concludes that cholesterol findings conflict and bone studies are too few and inconsistent for firm conclusions. Isoflavone receptor activity does not establish cardiovascular or fracture benefit, and short trials cannot settle long-term safety in hormone-sensitive conditions. [5]
How might it work?
Biochanin A and formononetin can be metabolized to genistein and daidzein. These compounds can interact with estrogen receptors, often with greater affinity for ER-beta than ER-alpha. Gut metabolism varies among people. Receptor activity is a biological hypothesis, not proof that an extract reproduces estrogen therapy or improves a clinical outcome. [1], [5]
What are the risks and interactions?
Clinical extracts have appeared generally well tolerated for up to two years, but that does not establish indefinite safety. Gastrointestinal symptoms, headache, rash or unusual bleeding should be recorded. [5]
Avoid during pregnancy and breastfeeding because safety is inadequate and NCCIH says use may be unsafe. Hormone-sensitive cancer or other estrogen-sensitive conditions require clinician review. Medicines that affect clotting also warrant pharmacist or prescriber review; do not infer a quantified interaction risk from the plant's coumarin-related constituents alone. [5]
Seek urgent care for heavy or unexplained bleeding, breathing difficulty, facial or throat swelling, fainting or symptoms of a blood clot or stroke.
Legal status in the United States and Canada
In the United States, red clover supplements are not FDA-approved treatments for hot flashes, osteoporosis or cardiovascular disease.
In Canada, licensed natural health products carry an NPN and product-specific label conditions. An NPN does not establish that all isoflavone extracts are interchangeable.
What should you monitor?
Record species, plant part, extract name, milligrams of extract, milligrams of total isoflavones, number of units, start date, medicines and reproductive context. Use a consistent daily count and severity score for hot flashes. Keep bleeding and adverse effects separate from symptom benefit.
What happens when you stop?
A predictable withdrawal syndrome and evidence-based taper are not established. Hot flashes may return to their untreated pattern. New or persistent bleeding requires assessment rather than automatic restart.
How should it be stored?
Keep capsules closed, dry, away from heat and out of children's reach. Follow the finished-product expiry date and discard damaged, damp or unexpectedly changed products.
How does red clover compare with other approaches?
Red clover is not menopausal hormone therapy, an SSRI/SNRI, gabapentin or an approved nonhormonal menopause medicine. Those options have different effect sizes, contraindications and monitoring. Black cohosh contains different constituents and should not share an isoflavone conclusion.
What do public communities add?
Public reports can reveal product-label confusion, gastrointestinal effects, bleeding concerns and perceived symptom changes. They cannot authenticate isoflavone content, establish hormone-sensitive safety or separate a treatment effect from the large placebo response observed in trials.
Common questions
Does red clover reduce hot flashes?
The pooled estimate suggests a modest average reduction, but large placebo-controlled trials were null. Individual results and products vary. [1]–[3]
Is 80 mg the proven best dose?
No. It is an isoflavone exposure used in named trials and an exploratory subgroup threshold, not a universal optimum. [1], [4]
Does 398 mg mean 398 mg of isoflavones?
No. In the Geller trial, 398 mg of extract supplied 120 mg isoflavones. [3]
Is red clover the same as estrogen therapy?
No. Its isoflavones interact with estrogen receptors, but the product, evidence and risks differ from prescription hormones.
Does it improve cholesterol or bone density?
The evidence is inconsistent and insufficient for a firm clinical conclusion. [5]
Can it be used after hormone-sensitive cancer?
Do not assume safety. Discuss the specific product with the oncology team.
Is it safe during pregnancy or breastfeeding?
NCCIH says it may be unsafe; avoid supplement use in these settings. [5]
Should red clover be cycled?
No evidence-based on/off cycling schedule is established.
Glossary
Terms used in this guide.
- Isoflavone
- A plant compound that can interact with estrogen receptors; red clover contains several isoflavones.
- Biochanin A
- A red-clover isoflavone that can be metabolized to genistein.
- Vasomotor symptoms
- Hot flashes and night sweats related to temperature-regulation changes.
- Weighted mean difference
- A pooled difference that gives studies statistical weight based on their precision.
- Placebo run-in
- A period before randomization when all participants receive placebo, often used to establish baseline adherence or response.
- Titration
- Changing an amount in planned steps. No general red-clover self-titration is established.
How this guide was researched
This draft prioritized the 2021 meta-analysis, the ICE, Geller and van de Weijer primary trials, and NCCIH's April 2025 fact sheet. Searches separated extract mass from isoflavone mass, final placebo comparisons from within-group change, and hot flashes from lipids, bone and safety.
Corrections to the legacy manuscript include keeping the large null trials beside the pooled signal, removing a universal 80 mg dose claim, and narrowing claims for cholesterol, bone and hormone-sensitive safety. Evidence was refreshed October 9, 2026.
How this guide was made
The source ledger records preparation, population, schedule, outcome and access level. Draft status means scientific, French-parity, asset and rendered-page review remain separate gates.
Research method, access and remaining gaps
Full text was available for the 2021 review and Geller trial; other primary identities and results were checked through PubMed records and abstracts, and current safety language through NCCIH.
Remaining gaps include extract equivalence, independent modern trials, uncommon harms, medicine interactions and long-term hormone-sensitive safety.
Sources
Search the current review, primary trials and official safety summary used for the material claims.
Showing 5 sources
- 01
Evaluation of Clinical Meaningfulness of Red Clover (Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ↗
Systematic review and meta-analysis
Eight trials and ten comparisons; pooled reduction 1.73 hot flashes/day with exploratory subgroup patterns.
- 02
Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. ↗
Randomized double-blind placebo-controlled trial
252 women; Promensil 82 mg/day, Rimostil 57 mg/day or placebo for 12 weeks; no clinically important final effect.
- 03
Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. ↗
Randomized double-blind placebo-controlled trial
89 women; red clover extract 398 mg/day supplying 120 mg isoflavones for 12 months; 57% reduction versus 63% placebo.
- 04
Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. ↗
Randomized double-blind placebo-controlled trial
30 women; Promensil 80 mg/day for 12 weeks after placebo run-in; small named-product positive trial.
- 05
Red Clover: Usefulness and Safety ↗
Official evidence and safety fact sheet
No conclusive benefit; inconsistent hot-flash, cholesterol and bone findings; apparent tolerance up to two years and pregnancy or breastfeeding caution.
No matching sources
Try a different term or show the full list.